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Available online 3 November 2017Background: Pericardial disorders are a common cause of heart disease, and themost common cause of pericarditis
in developing countries is tuberculous (TB) pericarditis. It has been shown that prednisolone added to standard
anti-TB therapy leads to a lower rate of constrictive pericarditis. We conducted a pilot study to evaluate the effect
of adjunctive prednisolone treatment on the concentration of inﬂammatorymarkers in pericardial tuberculosis, in
order to inform immunological mechanisms at the disease site.
Methods: Pericardial ﬂuid, plasma and saliva samples were collected from fourteen patients with pericardial
tuberculosis, at multiple time points. Inﬂammatory markers were measured using multiplex luminex analysis
and ELISA.
Results: In samples from 14 patients we conﬁrmed a strongly compartmentalized immune response at the disease
site and found that prednisolone signiﬁcantly reduced IL-6 concentrations in plasma by 8 hours of treatment,
IL-1beta concentrations in saliva, as well as IL-8 concentrations in both pericardial ﬂuid and saliva by 24 hours.
Conclusion: Monitoring the early effect of adjunctive immunotherapy in plasma or saliva is a possibility in
pericarditis.ease and
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Tuberculosis (TB) is themost common opportunistic infection in HIV-
1 infectedpersons in Sub-SaharanAfrica. Tuberculous pericarditis is an in-
ﬂammation of the pericardium caused byMycobacterium tuberculosis. It is
a life-threatening extrapulmonary formof TB that results in accumulation
of ﬂuid around the heart, potentially leading to constriction. In developed
countries it accounts for ~5% of all cases of acute pericarditis, compared
to up to 90% in Sub-Saharan Africa, where it is the most common cause
of pericardial effusions in HIV-1 co-infected patients [1]. Mortality in
these patients is up to 40% in the absence of anti-retroviral treatment, de-
spite antituberculosis therapy, pericardial drainage, or pericardiectomy
[2].
The recently completed Investigation of theManagement of Pericar-
ditis (IMPI), a large clinical trial examining the effect of prednisolone or
Mycobacterium indicus pranii or both added to the standard regimen of
isoniazid, rifampin, ethambutol and pyrazinamide showed, that neitherMolecular Medicine,
outh Africa.
This is an open access articlthe standard anti-TB therapy alone nor the addition of prednisolone to
chemotherapy resulted in a clinically satisfactory mortality reduction,
however the prednisolone group had a lower rate of constrictive
pericarditis and fewer hospitalisations compared to placebo [3]. Since
we have recently shown that pericardial tuberculosis is characterised by
a compartmentalized proﬁbrotic immune response, we hypothesised
that prednisolonehad a suppressive effect on the concentration of inﬂam-
matory and potentially proﬁbrotic cytokines in the pericardium [4].
In this pilot study we evaluated the effect of prednisolone on inﬂam-
matory markers in pericardial ﬂuid, plasma and saliva, in a subset of pa-
tients from the above clinical trial in order to improve our understanding
of immunological mechanisms at the disease site, which could inform
development of more targeted interventions. Speciﬁc analytes were
selected based on our recent analysis of differentially abundant inﬂam-
matory markers (at both RNA and protein level) between the blood
and pericardial ﬂuid compartments [4]. Additionally, we also evaluated
the hypothesis that inﬂammation induced cell death in the pericardial
compartment would be in part due to apoptosis, which is initiated by
two major pathways: the extrinsic (through ligation of death receptors
or TNF receptors) and intrinsic pathways (mitochondria mediated) [5].
Caspase 8 activation is an essential early step in the induction of thee under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
105J. Shenje et al. / IJC Heart & Vasculature 18 (2018) 104–108apoptosis by the extrinsic pathway, while Caspase 9 activation is part of
the intrinsic pathway, both leading to activation of Caspase 3 [6]. We
therefore also assessed the effect of prednisolone on the concentration
of Caspases 3, 8 and 9 in the pericardial ﬂuid and plasma.
2. Materials and methods
2.1. Patient population
Patients were recruited from Groote Schuur Hospital, Cape Town,
South Africa as part of an intensive pharmacokinetic sampling study of
the Investigation of the Management of Pericarditis (IMPI) trial, with a
computer-generated randomisation list as described previously [3,7].
Ethical approval for these studies was obtained from the Faculty of
Health Sciences Human Research Ethical Committee at the University
of Cape Town (Reference numbers 102/2003, 402/2005, 289/2007)
and as published [3,7]. Brieﬂy, patients were eligible for inclusion in
the trial if they were 18 years of age or older, had a pericardial effusion
requiring pericardiocentesis conﬁrmed by echocardiography, had
evidence of deﬁnite or probable tuberculous pericarditis and started
antituberculosis treatment less than a week before enrolment into the
comparison of prednisolone versus placebo arm of the IMPI trial and
providedwritten informed consent for inclusion in the study. Pericardi-
al ﬂuid, plasma and saliva were obtained from 14 patients at multiple
time points following randomisation to prednisolone/placebo for phar-
macokinetic studies to assess antibiotic penetration as described [7].
Pericardial samples were collected via a catheter which was left in the
pericardial space for 24 h post-pericardiocentesis. Not all samples
were available from all patients at all time points, thus the present
analysis evaluated the concentration of cytokines, chemokines and
caspases at 0, 8 and 24 h only.
2.2. Luminex multiplex assay for cytokines and chemokines
Mediators analysed in undiluted plasma (P), pericardial ﬂuid (PF)
and saliva (S) samples included IFN-gamma, IL-1alpha, IL-1beta, IL-6,
IL-10, IL-12p40, TNF, CXCL8 (IL-8) and CXCL10 (IP-10), using customized
Milliplex™ kits (HCYTOMAG-60 K, Millipore, St Charles, MO, USA) on the
Bio-Plex platform (Bio-Rad Laboratories, Hercules, CA, USA) as described
[8]. Caspases 3, 8 and 9 in undiluted pericardial ﬂuid and plasma were
measured using human in vitro ELISA kits from Abcam (Cambridge,
UK), following the manufacturer's recommendations.
2.3. Statistical analysis
Statistical analysis was performed using GraphPad Prism Version
7.0c for Mac. The normality of data was assessed using the D' AgostinoTable 1
Patient characteristics.
Patient
number
Age
(years)
Wt
(kg)
Gender HIV HAART ART
therapy
CD4
(cells/μl)
1 28 53 male Positive No N/A 115
2 29 40 female Positive No N/A 50
3 24 66 female Positive No N/A 42
4 56 82 male Negative N/A N/A 485
5 31 72 male Negative N/A N/A 319
6 51 53 female Positive Yes Tdf/FTC/EFV 159
7 24 45 female Positive No N/A 321
8 27 66 female Positive No N/A 135
9 44 52 female Positive No N/A 139
10 59 66 male Negative N/A N/A 874
11 45 70 male Negative N/A N/A 721
12 33 47 male Positive No N/A 116
13 25 73 male Positive No N/A a
14 27 a female Positive Yes Tdf/FTC/EFV 255
a Data not available.and Pearson normality test. As not all patients were sampled at all
time points, some data were not paired. Between group comparisons
of unpaired non-normally distributed data were analysed using the
Mann-Whitney U test. No correction for multiple comparisons was
performed.3. Results
Of the 14 patients nine were on placebo and ﬁve on prednisolone
(at a dose of 120 mg per day in the ﬁrst week). Patient characteristics
were previously described as part of themain study [7], with the subset
included in this pilot study being detailed in Table 1. Nine patients had
deﬁnite tuberculous pericarditis (3 on prednisolone and 6 on placebo)
and ﬁve had probable tuberculous pericarditis (2 on prednisolone and
3 on placebo). The pericardial protein measured in pericardial ﬂuid
wasmedian 61 g/l (IQR 55–67.5) in the deﬁnite TB patients andmedian
66 g/l (IQR 56–76) in the probable TB patients respectively, while the
ADA was median 87.3 U/l (IQR 43–127) and 51 U/l (32.8–67.6) in the
deﬁnite and probable patients respectively. There was no signiﬁcant
difference between the groups with respect to either parameter. There
was no difference between age and weight between the groups, gender
composition was male/female 5/4 and 2/3 for the placebo and prednis-
olone groups respectively. Seven out of nine patients in the placebo and
three out of ﬁve patients in the prednisolone group were HIV infected.
Only two patients were receiving antiretroviral treatment at the time
of the study, both in the placebo group (Table 1). Median CD4 counts
were not different between the groups (240 cells/ml for the placebo
and 139 cells/ml for the prednisolone group). Since our previous ﬁnd-
ings indicated that neither HIV-1 coinfection status, nor CD4 count or
pericardial ﬂuidMycobacterium tuberculosis culture result affected the
compartmentalized proﬁbrotic immune response [4], we combined
patients with and without HIV infection for analysis, as well as patients
with deﬁnite and probable pericarditis.
Results are summarised in Table 2, indicating themedian (IQR) of all
analytes measured in all samples at the tested time points. Since sam-
ples were collected before prednisolone administration, we combined
the baseline data to analyse the effect of compartmentalization: higher
concentrations of IFN-gamma, IL-10, IL-1beta, IL-6, IL-8, IP-10 and TNF
were found at the disease site compared to plasma at day 0, supporting
our previousﬁndings [4]. Interestingly, IL-1alpha and IL-12p40wasmost-
ly detectable in the saliva samples,which also contained elevated concen-
trations of IL-1beta, IL-8 and IP-10 compared to plasma. Only IL-6
concentrations were higher in the plasma, compared to saliva (p =
0.03) at baseline. Caspase 3, 8 and 9 were only detectable in the pericar-
dial ﬂuid as opposed to plasma (p = 0.02, 0.0001 and 0.03 respectively
for the three caspases measured).Creatinine
(μmol/l)
Globulin
(g/l)
Steroid
allocation
Pericardial
protein (g/l)
ADA
(units/l)
TB
microscopy
76 46 Placebo 58 Hemolyzed Positive
20 45 Placebo 54 83 Positive
43 56 Prednisolone 68 57 Positive
121 30 Placebo 62 133 Positive
82 36 Prednisolone 55 119 Positive
80 56 Placebo 50 53 Negative
257 56 Placebo 67 92 Positive
45 55 Prednisolone 70 26 Positive
65 56 Prednisolone 66 51 Negative
97 38 Prednisolone 62 33 Negative
109 47 Placebo 76 32 Negative
71 49 Placebo 61 130 Positive
73 a Placebo 55 38 Positive
41 74 Placebo 76 68 Negative
Table 2
Median (IQR) of all analytes measured in all samples.
Site N Time Group IFN-γ
pg/ml
IL-1α
pg/ml
IL-1β
pg/ml
IL-6
pg/ml
IL-10
pg/ml
IL-12p40
pg/ml
TNF
pg/ml
IL-8
pg/ml
IP-10
pg/ml
Caspase 3
pg/ml
Caspase 8
ng/ml
Caspase 9
ng/ml
Pericardial ﬂuid 14 D0 Combined 2061
648–3285
0
0–62
15
0–114
9064
8225–10,000
26
21–65
0
0–5
197
100–354
7670
1841–10,434
1414
1013–1646
93
0–313
7
5–16
35
30–73
5 D0 Prednisolone 1585
533–6363
0
0–149
0
0–109
9277
8533–9969
28
22–47
0
0–3
180
107–469
3725
1512–9987
1435
846–1537
134
0–250
6
5–14
31
24–82
3 8 h 1436
383–2903
0
0–213
0
0–177
9166
8269–9390
37
25–56
0
0–0
218
142–483
4635
2876–9677
1495
1050–1701
193
0–193
8
6–13
38
26–61
4 24 h 838
278–2696
0
0–20
0
0–42
8797
8102–9755
24
13–31
0
0–0
265
141–394
1834
1576–2890
1245
865–1335
48
0–137
6
4–9
32
24–42
9 D0 Placebo 2536
553–3687
0
0–111
18
7–292
8850
7243–10,254
22
17–83
0
0–10
213
99–291
9329
1903–10,855
1348
790–1887
88
0–403
7
5–20
36
30–91
6 8 h 1347
298–3485
2
0–18
14
8–74
9097
8058–9483
29
11–125
0
0–3
182
96–353
2603
2334–9106
1462
657–1972
72
0–216
10
8–17
41
31–70
6 24 h 927
482–2619
8
0–124
58
14–185
8695
6377–9394
16
8–46
1
0–18
175
83–299
7067
4180–9957
1758
908–1944
168
0–684
11
4–21
48
32–61
Plasma 12 D0 Combined 28
10–116
0
0–0
0
0–0
23
16–61
4
0–7
0
0–0
33
21–53
23
11–33
82
40–158
0
0–0
0
0–2
24
19–40
5 D0 Prednisolone 84
28–231
0
0–0
0
0–5
20
13–23
3
0–12
0
0–0
35
28–67
21
16–30
77
26–127
0
0–56
0
0–6
29
23–55
3 8 h 72
14–102
0
0–0
0
0–5
4
0–15
0
0–8
0
0–0
23
15–25
10
10–25
52
33–72
0
0–0
2
1–4
49
17–55
3 24 h 37
9–259
0
0–0
0
0–5
6
6–73
0
0–7
0
0–0
19
19–57
28
16–54
49
21–59
0
0–470
2
0–2
25
14–34
7 D0 Placebo 13
5–118
0
0–0
0
0–0
35
19–88
4
0–7
0
0–0
26
12–55
25
5–72
86
36–305
0
0–0
0
0–0
20
18–34
5 8 h 16
4–117
0
0–0
0
0–0
49
19–67
6
0–10
0
0–0
22
14–94
20
8–99
68
36–214
0
0–109
2
0–3
23
19–45
6 24 h 11
3–83
0
0–0
0
0–0
44
17–74
1
0–3
0
0–0
20
17–68
19
16–30
47
24–288
0
0–0
0
0–2
20
15–22
Saliva 12 D0 Combined 17
10–23
3393
949–11,180
28
18–144
11
2–28
15
1–25
18
0–39
15
9–80
295
134–961
1123
167–2316
nd nd nd
5 D0 Prednisolone 18
10–30
1758
980–8567
26
15–663
10
5–29
21
15–57
31
0–48
13
10–47
325
88–1257
1061
201–2420
nd nd nd
3 8 h 17
17–35
341
336–5752
12
5–20
5
1–10
37
4–40
37
10–86
14
7–20
52
32–55
139
45–762
nd nd nd
4 24 h 10
1–36
390
59–3341
11
2–14
6
1–11
28
2–63
23
0–88
12
3–15
44
3–117
92
30–552
nd nd nd
7 D0 Placebo 15
0–23
6473
722–12,416
30
17–146
11
0–29
3
0–22
11
0–39
59
6–210
265
156–486
1184
67–2361
nd nd nd
6 8 h 16
13–17
1399
401–13,354
14
4–56
8
4–30
4
1–37
0
0–2
22
4–110
140
22–234
345
90–1095
nd nd nd
7 24 h 15
11–23
2890
531–7632
26
17–105
10
2–12
5
0–77
0
0–32
26
5–56
163
94–361
376
240–2661
nd nd nd
N: number of patient samples available for analysis at speciﬁc time point; D0: day 0; nd: not done.
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107J. Shenje et al. / IJC Heart & Vasculature 18 (2018) 104–108Prednisolone signiﬁcantly decreased the concentration of IL-6 by 8 h
in plasma, compared to the patients who received placebo (Fig. 1A, p=
0.036, Mann Whitney U test). In pericardial ﬂuid, prednisolone signiﬁ-
cantly reduced IL-8 concentrations by 24 h (Fig. 1B, p = 0.03, Mann
Whitney U test), compared to the placebo treated patients. There
was a trend towards decreased IL-1beta concentrations, however signif-
icance was not reached due to low numbers (p = 0.06, not shown).
Finally in saliva, we found a signiﬁcant reduction in concentration of
both IL-8 and IL-1beta by 24 h of treatment in the prednisolone group
(Fig. 1C, p = 0.04, Mann Whitney U test; and Fig. 1D, p = 0.027,
MannWhitney U test), compared to the placebo group. The concentra-
tion of caspase 3, 8 and 9 did not appear to be affected by prednisolone
in any of the compartments evaluated.
4. Discussion
The largest clinical trial evaluating the effect of adjunctive predniso-
lone therapy showed no effect on the primary composite of death, cardiac
tamponade requiring pericardiocentesis or constrictive pericarditis,Fig. 1. Panel A. Concentration of IL-6 (pg/ml) in plasma at baseline, 8 and 24 h after initiation o
Whitney test). Concentration of IL-8 (pg/ml) in pericardial ﬂuid (Panel B) and saliva (Panel C)
decrease by 24 h in both pericardial ﬂuid and saliva (p = 0.03 and 0.04 respectively, Mann W
after initiation of prednisolone treatment, leading to signiﬁcant decrease by 24 h (p = 0.027, Mhowever, with respect to the secondary outcomes, the IMPI trial demon-
strated that prednisolone reduced the incidence of constrictive pericardi-
tis and the incidence of hospitalisations [3]. Here we hypothesised
that the antiinﬂammatory effects of prednisolone would also manifest
in reduced measurable concentrations of inﬂammatory cytokines and
chemokines. Our ﬁndings suggest that the beneﬁcial effect of predniso-
lone is associatedwith the suppression of inﬂammatorymediators IL-6,
IL-8 and IL-1beta.
These results support our previous ﬁndings described during the
treatment of tuberculosis associated immune reconstitution inﬂammato-
ry syndrome (TB-IRIS) with prednisone vs placebo [9], where prednisone
reduced the duration of hospitalisation and the number of outpatient
therapeutic procedures. At the same time, IL-6, IL-10, IL-12 p40, TNF,
IFN-gamma, and IFN-gamma-induced protein-10 (IP-10, CXCL10)
concentrations signiﬁcantly decreased in the serum of prednisone, but
not placebo, treated patients [10]. In a separate study we found that
adjunct corticosteroid therapy modiﬁes the inﬂammatory proﬁle of
those who develop TB-IRIS, with lower concentrations of IFN-gamma,
IP-10, TNF, IL-6, IL-8, IL-10, IL-12p40, and IL-18 [11]. Thus, the beneﬁcialf prednisolone treatment, which resulted in signiﬁcant reduction by 8 h (p = 0.036, Mann
at baseline, 8 and 24 h after initiation of prednisolone treatment, which led to signiﬁcant
hitney test). Panel D. Concentration of IL-1beta (pg/ml) in saliva at baseline, 8 and 24 h
ann Whitney test).
108 J. Shenje et al. / IJC Heart & Vasculature 18 (2018) 104–108effects of prednisone appear to be mediated via suppression of predomi-
nantly proinﬂammatory cytokine responses of innate immune origin,
similar to our current ﬁndings.
We reported earlier that cell-death enrichment factors were elevated
in pericardial ﬂuid [4] and hypothesised that TB antigen speciﬁc activated
T cells that enter the pericardiumand release INF-gammadie, thus poten-
tially activating the inﬂammasome pathway resulting in pyroptosis and
release of IL-1beta, ultimately leading to more cell death. Here we show
a trend towards decreased IL-1beta concentrations in the pericardial
ﬂuid of prednisolone treated patients, as well as higher concentrations
of caspases 3, 8 and 9 in the pericardial ﬂuid, thereby supporting our
hypothesis for compartmentalized inﬂammation induced apoptosis in
the pericardial ﬂuid.
This report is limited by the small sample size therefore the statisti-
cal signiﬁcance of the ﬁndings is weak. The small sample size further
limited our capacity to analyse the results based on the HIV status of
the patients, since it has been described that HIV infection is associated
with a lower incidence of pericardial constriction in patients with
presumed tuberculous pericarditis [12], and IL-13-secreting CD4 T
cells, which are reduced by HIV, regulate ﬁbrogenesis directly, through
stimulating collagen synthesis by ﬁbroblasts and indirectly by promoting
TGF-beta1 production bymacrophages [13]. However,we based our anal-
ysis strategy on our previous ﬁndings, that showed neither HIV-1 coinfec-
tion status, nor CD4 count or pericardial ﬂuidMycobacterium tuberculosis
culture result affected the compartmentalized proﬁbrotic immune re-
sponse with respect to the selected analytes wemeasured [4]. Additional
limitation of this pilot study is that pericardial ﬂuid sampling was
restrictedwithin 24 h of initiation of prednisolone therapy due to safety
concerns over leaving the pericardial catheter in the pericardial space
for a prolonged period of time.
These ﬁndings however are of interest because TB remains the lead-
ing cause of constrictive pericarditis in Africa. The treatment for chronic
pericardial tuberculosis leading to constriction is pericardiectomy,
which is associated with high mortality and morbidity but also prob-
lematic due to the fact that cardiac surgery is not widely available in
Africa [14]. Thus adjunctive immunotherapy that reduces the incidence
of constrictive pericarditis, andwhich could bemonitored bymeasuring
inﬂammatory markers in easily obtainable samples such as plasma or
saliva, might be beneﬁcial during early patient follow up in reducing
morbidity and possibly even mortality.
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